Investigating the Effects of Atezolizumab in People Whose Tumour DNA or RNA Indicates Possible Sensitivity
Last updated on July 2021Recruitment
- Recruitment Status
- Recruiting
- Estimated Enrollment
- Same as current
Summary
- Conditions
- Breast Cancer
- Gastrointestinal Cancer
- Genitourinary Cancer
- Gynecologic Cancer
- Head and Neck Cancer
- Lung Cancer
- Sarcoma
- Skin Cancer
- Unknown Primary Tumors
- Type
- Interventional
- Phase
- Phase 2
- Design
- Allocation: Non-RandomizedIntervention Model: Parallel AssignmentIntervention Model Description: Simon 2-stage design; 8 tumour-defined cohorts consisting of 8 to 24 participants each.Masking: None (Open Label)Primary Purpose: Treatment
Participation Requirements
- Age
- Between 18 years and 125 years
- Gender
- Both males and females
Description
Not Provided
Not Provided
Tracking Information
- NCT #
- NCT04273061
- Collaborators
- Hoffmann-La Roche
- Investigators
- Principal Investigator: Janessa Laskin, MD BC Cancer